Memorial Hospital Research Laboratories
The Charles Rudin Lab
Research
Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.
Featured News
Publications
Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. (2021) [PMID: 33446664]
People
Charles M. Rudin, MD, PhD
- Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
- MD, PhD, University of Chicago Pritzker School of Medicine
- rudinc@mskcc.org
- Email Address
- View physician profile
- Physician profile
Members
- Residency, Cornell University (Internal Medicine)
- MD, PhD, Columbia University
- BS, Stanford University
- BS, Northeastern University
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
Career Opportunities
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Charles M. Rudin discloses the following relationships and financial interests:
-
Amgen
Provision of Services -
Bridge Medicines
Provision of Services -
Daiichi Sankyo
Intellectual Property Rights -
Earli Inc.
Ownership / Equity Interests -
Harpoon Therapeutics, Inc.
Provision of Services -
Ipsen
Provision of Services
-
Jazz Pharmaceuticals
Provision of Services -
Merck Sharp & Dohme
Provision of Services -
Pfizer, Inc.
Provision of Services -
Seneca Therapeutics
Intellectual Property Rights -
Syros
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.